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Abstract 
Cigarette smoking is linked to negative health consequences in nearly every organ system 
in the body and has a huge economic burden worldwide (Tran, Ho, & Varghese Gupta, 2019).  
Smoking cessation should be a priority to all health care providers and patients. The case study 
focusses on smoking cessation for a 72-year-old woman with a 45-pack year history of cigarette 
smoking. Patient has attempted tobacco cessation but has been unsuccessful.  
Smoking cessation interventions help with smoking cessation maintenance. Smoking 
cessation relapse is least likely when effective pharmacologic and cognitive interventions are 
used in combination. Health care providers should be promoting smoking cessation in all patient 
who currently smoke. They should also be supporting patients with their physical and 
psychological needs during the smoking cessation process and throughout their lifetime to 
prevent relapse. Pharmacological interventions include nicotine replacement therapies, 
















Despite smoking related disease and risk being well known, smoking cigarettes remains a 
serious health epidemic. It is estimated that about one third of the world’s adult population 
smokes (Claudio Pereira, Gritsch, Passos, & Furtado, 2018).  Tobacco use is the leading 
preventable cause of cancer and cancer death. It is linked to many types of cancer including, oral 
cavity and pharynx, larynx, esophagus, lung, bronchus and trachea, stomach, kidney, pancreases, 
liver, urinary bladder, uterine, cervix, colon, and acute myeloid leukemia (Gallaway et al., 2019). 
Smoking accounts for 70% of lung cancers, 42% of chronic respiratory diseases, and 10% of 
cardiovascular (Claudio Pereira et al., 2018).  
Smoking cessation can be very difficult for patients. A study showed that 70% of 
smokers have the desire to quit and 46% have attempted to quit. Over 50% of these smoking 
cessation attempts have relapsed in one year (Durmus Kocak et al., 2015).  Forty-eight percent of 
smoking cessation relapse occurs in the first month (Durmus Kocak et al., 2015). There are 
pharmacologic, cognitive, and combination programs to assist with smoking cessation and 
preventing relapse. Each individual has their own motivation and journey to successful smoking 
cessation.  
Case report includes a 72-year-old woman with a 45-pack year history of cigarette use. 
She has made multiple attempts of smoking cessation over the years but has not been successful 
long term. She currently has the desire to quit smoking and is seeking assistance from her 
primary care provider to help her be successful with smoking cessation.  
Case Report 
A 72-year-old Caucasian female presents to the clinic for follow up care after right hip 
fracture. Patient fell and broke her right hip. She had a right hip ORIF. She spent three days in 
the hospital without complications. She denies fever, chills, nausea, vomiting, and loss of 
SMOKING CESSATION  5 
 
appetite. Denies redness, swelling, or warmth at the incision site. Denies numbness and tingling 
of lower extremities. Denies cough, shortness of breath, chest pain, and palpitations.  She states 
her pain is well managed with Tylenol. She states she is capable of ambulating independently 
and has good movement of the hip. She is able to perform activities of daily living 
independently. She lives independently but has family in town that helps with household tasks.  
She reports a medical history of Chronic Obstructive Pulmonary Disease (COPD), anemia, 
hypertension, hypercholesterolemia, and smoker. She is a current every day smoker with a 45-
pack year history.  She has had unsuccessful attempts of quitting in the past. She currently has 
the desire to quit smoking and is wanting assistance.  She desires to establish care with a primary 
care provider.  
Patient medications include: Fluticasone propionate and salmeterol 250/50 1 puff BID, 
Prednisone taper for COPD exacerbation that was finished yesterday, Losartan 50mg PO daily, 
Metoprolol 50mg PO BID, Paroxetine 20mg PO daily, Quetiapine 200mg PO BID, Lipitor 20mg 
PO daily, Multivitamin 1 tablet PO daily, Iron sulfate 325mg PO BID. Patient has no known 
drug allergies.  
Physical examination reveals her vitals are the following: BP 138/70, Pulse 72, 
Respiratory rate 18, O2 saturation 92%, and temperature 98.6. She is alert, oriented, and in no 
acute distress. Head is normocephalic without obvious abnormality, atraumatic. Eyes are 
conjunctivae/corneas clear. PERRL, EOM's intact. Ears have normal TM's and external ear 
canals clear.  Nose include Nares normal. Septum midline. Mucosa normal. No drainage or sinus 
tenderness. Throat has oropharynx pink & moist without lesions or evidence of thrush and lips, 
mucosa, and tongue normal; teeth and gums normal. Neck is supple, symmetrical, trachea 
midline and no adenopathy.  Lung sounds are clear with no increased work of breathing. COPD 
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is well managed at this time after recently being treated for an exacerbation. Heart is regular rate 
and rhythm without murmur.  Abdomen is soft and non-tender. Bowel sounds active. No 
organomegaly felt.  The incision on her right hip is healing well with no signs of infection.  No 
edema to legs bilaterally. Patient has stable gait when ambulating in room. Good range of motion 
to hip/legs bilaterally. 
Assessment for this patient includes status post right hip open reduction internal fixation, 
current smoker with desire to quit, screening for lung cancer, and need to establish primary care 
provider. The follow up plan was discussed with the patient and she is in agreement with the 
plan. Follow up with primary care provider or surgeon if right hip pain shows signs of infection 
developing such as increasing pain, swelling, drainage, redness, and warmth. Encouraged to do 
weight bearing exercises. Continue to increase activity as tolerated.  
Smoking cessation is the patient’s priority.  Patient was instructed to choose a smoking 
quit date. Prescription for Nicotine 21mg patches given. Apply to clean, dry, hairless skin. 
Remove patch after 16-24 hours and place patch in new area. Do not use same area as old patch 
for at least one week.  After 6 weeks decrease to 14mg patch than at week 9 decrease to 7mg 
patch and then wean off. Call ND Quit line at 1-800-QUITNOW for support and assistance with 
quitting. Will also consider referral to local tobacco cessation specialists. Will consider 
additional cessation medications if indicated by unsuccessful quit attempts or relapse. 
Recommended lung cancer screening with low dose CT scan due to smoking history. Patient in 
agreement. Will schedule with radiology department. 
Set up appointment next week to establish care. We will do a yearly physical 
examination, labs, discuss preventative care (such as colonoscopy, and bone density scan) and 
evaluate management of chronic health conditions. Continue all current medications at this time. 
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Encouraged to increase calcium intake to 1200mg daily with dairy intake or supplements. 
Questions answered and patient in agreement. 
Literature Review 
The patient in the case study has a female 45-pack year history of cigarette use with 
complications of COPD. She had admitted to multiple cessation attempts but was unable to 
successfully remain free of tobacco use. She currently has a desire to quit. She needs assistance 
with a smoking cessation plan that will make her smoking cessation successful long term.  
Center for Disease Control and Prevention (2014) noted that Tobacco use is the leading cause of 
preventable disease and death in the United States and it is estimated that tobacco use cost $300 
billion annually.  
Smoking cessation is a chronic process that can be divided into specific phases. 
Motivation is the period prior to a smoker being ready to make a quit attempt. Precessation is the 
period prior to a quit attempt after a smoker has committed to making a quit attempt. Cessation is 
the two-week period following and including a quit attempt. Maintenance is the time beyond the 
first two week of a quit attempt (Garey et al., 2018).  Relapse prevention is interventions that 
focus on maintenance after acute treatment phase is completed (Livingstone-Banks, Norris, 
Hartmann-Boyce, West, Jarvis, & Hajeck, 2019).  Health care providers can have an impact on 
each of these phases. This paper will focus on strategies to assist patients with the maintenance 
of smoking cessation. There are pharmacologic, cognitive, and combination programs to assist 
with smoking cessation and prevent relapse. Health care providers are given multiple 
opportunities for motivating and assist smokers to quit throughout the different phases of 
smoking cessation. Over 80% of smokers see a health care provider at some point each year, and 
most smokers desire and expect their provider to talk to them about quitting smoking and are 
open to their providers’ advice (CDC, 2014).  
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Research is needed for finding the best strategies for the preventing relapse of smoking 
cessation. Research for this paper was completed using CINAHL and PubMed search engines. 
Search terms used a combination of “smoking cessation,” “preventing relapse,” “smoking 
cessation maintenance” “nicotine replacement therapy,” “bupropion,” “varenicline,” and 
“cognitive therapy.” Search was limited to articles less than five years old, English, and full text.  
Success of smoking cessation maintenance can depend on age, motivation to quit 
smoking, number of past quit attempts, and smoking urges. Interventions can be focused on 
motivation and smoking urges. Assessment of these factors by a health care provider prior to a 
smoking cessation attempt can lead to increased quit success (Garey et al. (2019).  
Pharmacological treatments 
 Pharmacological therapies approved by the United States Food and Drug Administration 
include varenicline, nicotine replacement therapy and bupropion. Varenicline agonizes and 
blocks alpha-4-beta-2 nicotinic acetylcholine receptors. It works for smoking cessation by 
decreasing tobacco withdrawal, smoking pleasure and cravings (Woo & Robinson, 2016). 
Nicotine replacement therapy is used in the forms of gum, patch, inhaler, nasal spray and 
lozenges. The nicotine replacement is used to decrease symptoms of nicotine withdrawal and 
cravings (Woo & Robinson, 2016). Bupropion is an antidepressant used to assist with smoking 
cessation and the exact action on smoking cessation is unknown (Woo & Robinson, 2016). The 
mechanism of actions is thought to be blockage of neurotransmitter reuptake at the synapse 
(Tran, Ho, & Varghese Gupta, 2019).  The medications are often combined in hopes to increase 
the success of smoking cessation maintenance.  
A study compared participates who had more neural response to pleasure or cigarette 
related pictures. It showed that for individuals who respond more to pleasure than cigarettes had 
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a greater chance of remain abstinence regardless of medications. In those that responded more to 
cigarette images had higher smoking cessation rates at three months with varenicline compared 
to bupropion (Cinciripini et al., 2017). Varenicline showed increased rates of smoking cessation 
at three months compared to nicotine replacement therapies (Rohsenow et al., 2017; Walker et 
al., 2018). Extended treatment longer than twenty-four weeks with varenicline helps to prevent 
relapse compared to shorter treatment courses of eight to twelve weeks (Livingstone-Banks et 
al., 2019). Varenicline alone is proven to be as effective as a combination of bupropion and 
varenicline for smoking abstinence rates (Tran, Ho, & Varghese Gupta, 2019).  
Nicotine replacement therapies can be used to minimize the craving and withdrawal 
symptoms. Nicotine replacement therapies are designed to used for weeks and weaned down. 
When nicotine replacement is not adhered to for at least five weeks, there is a higher risk for 
relapse of smoking by six months (Raupach, Brown, Herbec, Brose, & West, 2014).  Combining 
different methods of nicotine replacement therapies is more effective than a single method in 
smoking cessation maintenance. However additional research is needed to determine which 
combinations and doses provides the highest effectiveness (Tran, Ho, & Varghese Gupta, 2019).  
According to the Cochrane review there is not enough evidence to determine if extended use of 
nicotine replacement therapy for twenty-four or fifty-two weeks increases smoking cessation 
maintenance rates (Livingstone-Banks et al., 2019).  
Bupropion was found to be effective for smoking cessation maintenance at one and two 
years compared to placebo (Livingstone-Banks et al., 2019).  A study showed that higher doses 
of bupropion had higher rates of smoking cessation at six weeks but after one year the lower 
doses of had similar rates of smoking cessation maintenance rates (Tran, Ho, & Varghese Gupta, 
2019).  Bupropion use extended longer than twenty-four weeks did not increase rates of smoking 
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cessation maintenance (Livingstone-Banks et al., 2019).  When nicotine replacement therapy was 
combined with bupropion it showed to be more effective than Nicotine replacement therapy or 
bupropion alone (Livingstone-Banks et al., 2019).  
When comparing varenicline, nicotine replacement therapy, bupropion, and combination 
of nicotine replacement & bupropion to placebo, varenicline that the best rates of relapse 
prevention at one year (Livingstone-Banks et al., 2019). Due to showing the highest rates of 
preventing smoking cessation relapse especially when used for extended amounts of time of 
longer than twenty-four weeks, varenicline should be considered by health care providers for 
patients who desire smoking cessation. 
Cognitive Treatments 
 Cognitive treatments are commonly used in smoking cessation treatment and 
maintenance. Cognitive therapy works on the mental ability to overcome nicotine addiction 
through using mindfulness, motivation, self-efficacy, and support. 
One study looked a psychological factors that played a role in smoking cessation attempts 
and smoking cessation maintenance. Motivation which is defined as “an inner drive to behave or 
act in a certain manner” is needed for quit attempts. Smoking cessation maintenance requires 
both motivation and self-efficacy which is defined as “belief in one’s own ability to execute a 
particular behavioral sequence in order to achieve a goal or an outcome.” (Lee, Catley, & Harris, 
2014). Both motivation and self-efficacy should be evaluated by health care providers to assists 
patients with smoking cessation maintenance.  
Cognitive behavior therapy (CBT) is used for smoking cessation, but the length of 
therapy is controversial. A study indicated that extended cognitive behavior therapy as defined as 
therapy longer than twenty-six weeks did not increase success rates compared to therapy shorter 
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than twenty-six weeks (Laude et al., 2017).  In the study, extended CBT group attendance rates 
were 65% for weeks one to twenty-six and rates dropped to 31% percent for weeks twenty-seven 
to forty-eight. Extended CBT treatment may cause fatigue and decreased rates of ongoing 
treatment (Laude et al., 2017).   
Individuals with mental illness have a disproportionally higher rate of smoking. Having 
two or more lifetime mental illness decreased the rate of smoking cessation by 15% compared to 
an 11% percent decrease in smoking cessation in those with depression alone (Huffman, 
Bromberg, & Augustson, 2018).  Having a mental illness is a risk factor for relapse even after a 
year of smoking cessation (Álvarez Gutiérrez et al., 2016). Teaching mindfulness to smokers can 
have a positive effect on mental health. Mindfulness can help patient with mental illness with 
smoking cessation maintenance. Mindfulness can have a positive impact on quality of life by 
increasing motivation to continue treatment and thus preventing relapse (De Souza et al., 2015). 
Mindfulness also makes an individual more aware of what their smoking triggers are and how to 
avoid them. Triggers may include alcohol, smoke exposure, and stress. Regular alcohol intake of 
up to one drink a day was associated with increased relapse rates of 31 % compared to 14% in 
those that did not consume alcohol (Durmus Kocak et al., 2015).  Having exposure to other 
smokers increase the risk for relapse, especially having another smoker in the same household. 
(Durmus Kocak et al., 2015).  Higher rate of relapse is associated with starting smoking at 
younger ages. (Durmus Kocak et al., 2015).  Studies showed that mindfulness can have a 
reduction in stress, irritability, lack of concentration, depression, anxiety and other psychiatric 
symptoms. The reduction in negative psychological states increase adherence to abstinence from 
tobacco and other substances (De Souza et al., 2015). Individuals being mindful of stress 
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triggers, use of other substances, and smoke exposure can increase their likelihood of being 
successful with smoking cessation maintenance.  
Smoking is higher in rural areas compared to urban areas.  Rural areas have less access to 
cessation services (Noonan et al., 2018).  Text and telephone based smoking cessation services 
can be used to reach individuals living in rural area and those who have difficulty attending 
smoking cessation programs in person. Quit lines are state based telephone services that provide 
callers with counseling information on how to quit, and medications for smoking cessation. A 
study showed that text-based schedule gradual reduction had higher rates of smoking cessation 
than text-based support messages alone. The schedule gradual reduction had participants smoke 
as usual the first week and send a message every time they smoked. The number of cigarettes 
was calculated and then the next week the number of cigarettes was cut by one-third and 
participants were asked only to smoke when messaged over the phone.  Over the next couple 
weeks, the number of cigarettes was decreased.  Participants were to respond to each message if 
they smoked or not. The study states that text-based messages are a feasible way to assist 
individuals with smoking cessation and maintenance (Noonan et al., 2018).  The constant contact 
through the text messages helps with keep the individuals accountable and aware of the smoking 
triggers. Ease of access for the patient should be considered when deciding what type of support 
program to increase rates of successful completion. 
Smoking rates are significantly higher in adults that live below the poverty line compared 
to the general public (Bailey, Heintzman, Jacob, Puro, & Marino. 2018).  Cost estimator may be 
helpful for some patient’s motivation if they see how much money they could save with smoking 
cessation.  For example, a patient with a 45-pack year history and an average cost of $3.15 per 
pack of cigarettes. This will cost this patient over $51,000 over the 45 years. The upfront cost of 
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cigarette can be easily calculated but it is more difficult to estimate the secondary costs of 
increased health costs. Tobacco cessation treatments are very cost effective as they reduce health 
care costs, increase productivity, and reduce absenteeism (CDC, 2014). Showing a patient, the 
direct cost of cigarette use can be helpful in motivating them to prevent smoking cessation 
relapse.  
Cognitive therapy should be provided to patient through face to face interaction, phone, 
or text-based resources depending on what the patient prefers and has access to.  Therapy 
services work on increasing mindfulness, motivation, & self-efficacy while providing support 
throughout the smoking cessation process.   
Conclusion 
The act of smoking cessation is just the beginning of a journey. Smoking cessation has 
high rates of relapse. Health care providers can assist with prevention of relapse. Interventions 
include pharmacologic, cognitive and combinations of both. Healthcare providers and the patient 
need to work as a team to make smoking cessation a life long success.  
Learning Points 
• Readiness for smoking cessation and evaluation of smoking cessation maintenance 
should be addressed by health care providers at every visit.  
• Smoking cessation pharmacological and psychological interventions should be used in 
combination for the highest cessation and maintenance rates.  
• Varenicline is the most successful medication for preventing relapse of smoking 
cessation. Varenicline is most successful for long term smoking cessation when used for 
longer than 24 weeks.  
• Combinations of nicotine replacement therapy and Bupropion increases the effectiveness 
of preventing relapse compared to single drug therapy.  
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